# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Johnson & Johnson reports first-quarter earnings, with adjusted EPS up 12.4% and sales up 2.3%. Analysts optimistic about s...
Johnson & Johnson (NYSE: JNJ) reported better-than-expected first-quarter earnings on Tuesday.
RBC Capital analyst Shagun Singh maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target fr...
Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
B of A Securities analyst Geoff Meacham maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and lowers the price targe...
Investors remain on edge as geopolitics continue to shape market trends, with Israel mulling a response to Iran while the U.S. ...
On Tuesday, Johnson & Johnson (NYSE: JNJ) delivered a rather mixed first quarter report. Adjusted earnings surpassed estima...
Johnson & Johnson reports Q1 results: adjusted EPS $2.71 (up 12.4% Y/Y), sales $21.38B (up 2.3% Y/Y). Explore pharma giant&...